News

Filter

Current filters:

PharmaceuticalKeppra

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

UCB agrees $34.4 million settlement for off-label promotion of Keppra in USA; Novo to pay $25 million over NovoSeven

13-06-2011

The US subsidiary of Belgian pharmaceutical manufacturer UCB SA (Euronext Brussels: UCB) last week pleaded…

DiabetesKeppraLegalMarkets & MarketingNeurologicalNorth AmericaNovo NordiskNovoSevenPharmaceuticalUCB

Pipeline epilepsy agents will struggle to emulate past successes

28-05-2010

Despite the upcoming launch of several new brands, independent market analyst Datamonitor expects the…

KeppraMarkets & MarketingNeurologicalPharmaceuticalResearchUCB

Mylan grows fourth quarter 2009 earnings and predicts strong profit growth ahead

02-03-2010

US generic drugmaker Mylan has exceeded quarterly profit expectations thanks to a strong performance…

FinancialGenericsKeppraKeppra InjectionLevetiracetamPharmaceutical

COMPANY SPOTLIGHT

Menarini

Back to top